A high risk pediatric acute myeloid leukemia with an extremely poor prognosis. The blasts show bright CD56 expression, dim-to-negative expression of CD45 and CD38, and lack of HLA-DR expression. This immunophenotype was named after one of the pediatric patient''s initials (RAM), from Children''s Oncology Group (COG) clinical trial AAML0531. [from
NCI]